5 MAGI Euregio, Bolzano, Italy.
6Department of Oncology, University of Lausanne and Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Category: genetics – Page 26
Semaglutide May Slow the Pace of Epigenetic Aging
While GLP-1 drugs can curb cardiometabolic dysfunction, reducing the risk of life-limiting and life-threatening diseases that would otherwise shorten health and lifespan, mechanistic evidence that they directly influence the biology of aging remains limited.
Can GLP-1 drugs rewind the epigenetic clock?
UCSD researchers conducted a post hoc analysis of a Phase 2b clinical trial evaluating the use of semaglutide in human immunodeficiency virus (HIV)-associated lipohypertrophy (HALS).
Proton pump rhodopsins for optogenetic manipulation of biological activities and beyond
(H2O), the principal component of living organisms including humans, dissociates into H+ and OH-in aqueous environments, and the resulting H+ concentration determines both cellular pH and the proton motive force (PMF) across cellular membranes. These physicochemical parameters are fundamental regulators of a wide range of biological processes. Optogenetics enables the manipulation of biological and cellular functions using light, typically through the ectopic expression of microbial rhodopsins as photoreceptive proteins in target cells or organs.
Plasma agriculture makes strides toward super-seeding conventional methods
Occasionally, the sun unleashes powerful flares and coronal mass ejections, which hurl plasma and energetic particles into space. On the infant Earth, this solar activity drove cascades of atmospheric chemical reactions that may have helped form the building blocks of life. More recently, scientists have discovered that applying plasma to seeds in a controlled way can trigger similar activity, making them faster-growing and more resilient. Researchers at Nagoya University and Kyushu University in Japan have compiled a comprehensive review of this new field—termed “plasma agriculture”—as a potential sustainable solution to address global food shortages.
The word plasma brings to mind a hot, ionized inferno that makes up the fourth state of matter. But the plasma used here is different. By applying high voltage to air or any gas, electrons are stripped from a tiny fraction of its molecules and gain very high energies. These electrons zipping around can effectively mimic the behavior of plasma even though the bulk of the gas remains at room temperature.
This low-temperature plasma can be applied directly to seeds without burning them. Excessive use of chemicals and genetic modification of plants cause concern for many people. Instead, plasma agriculture can offer similarly high crop yields without invasive intervention.
A Last-Resort Antibiotic Is Losing The Battle Against a Dangerous Hospital Bug
The combination drug ceftazidime-avibactam (CZA) is a last line of defense against the common Pseudomonas aeruginosa hospital bug: It’s the drug that gets called in when nothing else works, but there’s now evidence that it may not keep working for long.
Based on an analysis of two critically ill patients with P. aeruginosa infections, the bacteria are developin g genetic mutations that change the enzymes they produce – and can ward off an attack from CZA.
Researchers led by a team from Tongji University in China have now published a new paper in Microbiology Spectrum detailing the mutations and what it might mean for fighting P. aeruginosa in the future.
Study Maps Brain Stem Networks to Help Patients Regulate PTSD
A new study combines rodent optogenetics and 7T fMRI to map periaqueductal gray regulation, aiming to develop neurofeedback for PTSD.
New genetic reference map accelerates human stem cell research
A team led by bioengineers at the University of California San Diego has developed a genome-scale reference map that details how individual genes control the functions and identities of human stem cells.
New heart disease mechanism revealed: Next-generation targeted therapy shows benefit across mutation types
A study led by the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), working in collaboration with an international research team, has identified a new molecular mechanism involved in hypertrophic cardiomyopathy, the most common inherited cardiovascular disease.
The research, published in Nature Cardiovascular Research, also demonstrates that mavacamten—the first targeted therapy available for this condition—is effective across different types of genetic mutations.
Hypertrophic cardiomyopathy is the most common inherited heart disease and the leading cause of sudden cardiac death in young people and athletes.
Ultrasound-based pacemaker noninvasively steadies the heart
MIT engineers have developed a noninvasive pacemaker that stimulates the heart using ultrasound. The design could one day provide a surgery-free alternative to traditional cardiac implants.
The new device is designed as a small sticker that can be worn on the chest. Tiny transducers on the sticker send ultrasound pulses through the chest to stimulate the heart. The ultrasound waves trigger the opening of certain ion channels in heart cells, an effect the researchers amplified through genetic engineering. When the channels open, they let in calcium, which signals a heart cell to squeeze and beat.
In experiments in the lab, the researchers applied ultrasound waves to engineered human cardiac cells and found that the pulses effectively maintained the cells’ healthy contractions. They also tested the ultrasound sticker on rats and found the device quickly, safely, and noninvasively corrected arrhythmias and restored normal, regular heart contractions.
Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise
Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds promise for treating myeloproliferative neoplasms. A new study from scientists at St. Jude Children’s Research Hospital showed that inhibiting menin significantly extended survival and reversed multiple disease features in preclinical models. The findings were published today in Cancer Cell.
Menin is best known as a therapeutic vulnerability in certain types of acute leukemia, including those with KMT2A gene rearrangements or NPM1 mutations. Menin inhibitors, such as revumenib, have greatly improved treatment for these cancers and are approved by the Food and Drug Administration (FDA). However, menin inhibition can reduce megakaryocytes (normal platelet-forming cells) and decrease platelet counts. Producing too many megakaryocytes is a hallmark of diseases called myeloproliferative neoplasms, which are slow-developing, rare blood cancers.
John Crispino, Ph.D., MBA, St. Jude Division of Experimental Hematology director and Department of Hematology member, tested whether inhibiting menin could be a viable therapeutic strategy for myeloproliferative neoplasms.